Literature DB >> 30504330

Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions.

Sara R Vazquez1.   

Abstract

Oral anticoagulants are commonly prescribed but high risk to cause adverse events. Skilled drug interaction management is essential to ensure safe and effective use of these therapies. Clinically relevant interactions with warfarin include drugs that modify cytochrome 2C9, 3A4, or both. Drugs that modify p-glycoprotein may interact with all direct oral anticoagulants, and modifiers of cytochrome 3A4 may interact with rivaroxaban and apixaban. Antiplatelet agents, nonsteroidal anti-inflammatory drugs, and serotonergic agents, such as selective serotonin reuptake inhibitors, can increase risk of bleeding when combined with any oral anticoagulant, and concomitant use should be routinely assessed. New data on anticoagulant drug interactions are available almost daily, and therefore, it is vital that clinicians regularly search interaction databases and the literature for updated management strategies. Skilled drug interaction management will improve outcomes and prevent adverse events in patients taking oral anticoagulants.
© 2018 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30504330      PMCID: PMC6246002          DOI: 10.1182/asheducation-2018.1.339

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  81 in total

Review 1.  Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Shashi Kumar; Stephan B Danik; Robert K Altman; Conor D Barrett; Gregory Y H Lip; Saurav Chatterjee; Gary S Roubin; Andrea Natale; Jacqueline S Danik
Journal:  Cardiol Rev       Date:  2016 Sep-Oct       Impact factor: 2.644

2.  Delayed de-induction of CYP2C9 compared to CYP3A after discontinuation of rifampicin: Report of two cases
.

Authors:  Soichi Shibata; Harumi Takahashi; Akiyasu Baba; Kei Takeshita; Koichiro Atsuda; Hajime Matsubara; Hirotoshi Echizen
Journal:  Int J Clin Pharmacol Ther       Date:  2017-05       Impact factor: 1.366

3.  Venous thromboembolism due to suspected interaction between rivaroxaban and nevirapine.

Authors:  Duane Bates; Bruce Dalton; Janet Gilmour; Jeff Kapler
Journal:  Can J Hosp Pharm       Date:  2013-03

4.  Development of Left Atrial Thrombus After Coadministration of Dabigatran Etexilate and Phenytoin.

Authors:  Nicole Hager; Jennifer Bolt; Lori Albers; Wladyslaw Wojcik; Patrick Duffy; William Semchuk
Journal:  Can J Cardiol       Date:  2016-10-28       Impact factor: 5.223

5.  Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.

Authors:  Christopher P Cannon; Deepak L Bhatt; Jonas Oldgren; Gregory Y H Lip; Stephen G Ellis; Takeshi Kimura; Michael Maeng; Bela Merkely; Uwe Zeymer; Savion Gropper; Matias Nordaby; Eva Kleine; Ruth Harper; Jenny Manassie; James L Januzzi; Jurrien M Ten Berg; P Gabriel Steg; Stefan H Hohnloser
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

6.  Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired Subjects.

Authors:  Mohamed Ismail; Vincent H Lee; Christina R Chow; Christopher M Rubino
Journal:  J Clin Pharmacol       Date:  2017-12-14       Impact factor: 3.126

7.  Single-dose fluconazole for vulvovaginal candidiasis: impact on prothrombin time in women taking warfarin.

Authors:  Mark A Turrentine
Journal:  Obstet Gynecol       Date:  2006-02       Impact factor: 7.661

8.  Association of Selective Serotonin Reuptake Inhibitors With the Risk for Spontaneous Intracranial Hemorrhage.

Authors:  Christel Renoux; Sarah Vahey; Sophie Dell'Aniello; Jean-François Boivin
Journal:  JAMA Neurol       Date:  2017-02-01       Impact factor: 18.302

9.  Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.

Authors:  Greg Flaker; Renato D Lopes; Elaine Hylek; Daniel M Wojdyla; Laine Thomas; Sana M Al-Khatib; Renee M Sullivan; Stefan H Hohnloser; David Garcia; Michael Hanna; John Amerena; Veli-Pekka Harjola; Paul Dorian; Alvaro Avezum; Matyas Keltai; Lars Wallentin; Christopher B Granger
Journal:  J Am Coll Cardiol       Date:  2014-10-14       Impact factor: 24.094

10.  Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.

Authors:  Benjamin A Steinberg; Anne S Hellkamp; Yuliya Lokhnygina; Jonathan L Halperin; Günter Breithardt; Rod Passman; Graeme J Hankey; Manesh R Patel; Richard C Becker; Daniel E Singer; Werner Hacke; Scott D Berkowitz; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf; Jonathan P Piccini
Journal:  Heart Rhythm       Date:  2014-05-13       Impact factor: 6.343

View more
  9 in total

1.  Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method.

Authors:  Romain Siriez; Lütfiye Alpan; Kossay Elasaad; Philippe Devel; Julie Laloy; Jean-Michel Dogné; Jonathan Douxfils
Journal:  J Thromb Thrombolysis       Date:  2020-04       Impact factor: 2.300

Review 2.  Intrathecal Baclofen Monotherapy and Polyanalgesia for Treating Chronic Pain in Patients with Severe Spasticity.

Authors:  Anuj Marathe; Sameer Allahabadi; Alaa Abd-Elsayed; Michael Saulino; Jonathan M Hagedorn; Vwaire Orhurhu; Jay Karri
Journal:  Curr Pain Headache Rep       Date:  2021-12-11

3.  A Dangerous and Unrecognized Interaction of Apixaban.

Authors:  Hussam Ammar; Rukma R Govindu
Journal:  Cureus       Date:  2021-11-18

4.  Simultaneous Characterization and Determination of Warfarin and Its Hydroxylation Metabolites in Rat Plasma by Chiral Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Shasha Jin; Zhihong Li; Qing Yang; Boyu Fang; Xiaoqiang Xiang; Chao Peng; Weimin Cai
Journal:  Pharmaceutics       Date:  2022-05-27       Impact factor: 6.525

5.  Detecting direct oral anticoagulants in trauma patients using liquid chromatography-mass spectrometry: A novel approach to medication reconciliation.

Authors:  Sudha Jayaraman; Jonathan H DeAntonio; Stefan W Leichtle; Jinfeng Han; Loren Liebrecht; Daniel Contaifer; Caroline Young; Christopher Chou; Julia Staschen; David Doan; Naren Gajenthra Kumar; Luke Wolfe; Tammy Nguyen; Gregory Chenault; Rahul J Anand; Jonathan D Bennett; Paula Ferrada; Stephanie Goldberg; Levi D Procter; Edgar B Rodas; Alan P Rossi; James F Whelan; Ventaka Ramana Feeser; Michael J Vitto; Beth Broering; Sarah Hobgood; Martin Mangino; Michel Aboutanos; Lorin Bachmann; Dayanjan S Wijesinghe
Journal:  J Trauma Acute Care Surg       Date:  2020-04       Impact factor: 3.697

6.  Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study.

Authors:  Spyridon Xynogalos; David Simeonidis; George Papageorgiou; Abraham Pouliakis; Nikolaos Charalambakis; Evangelos Lianos; Evridiki Mazlimoglou; Alexandros-Nikolaos Liatsos; Christos Kosmas; Nicolaos Ziras
Journal:  Support Care Cancer       Date:  2022-05-12       Impact factor: 3.359

7.  The edoxaban-M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma.

Authors:  Romain Siriez; Halil Yildiz; Céline Bouvy; Hélène Haguet; Vincent Maloteau; Michaël Hardy; François Mullier; Jean-Michel Dogné; Philippe Hainaut; Jonathan Douxfils
Journal:  Res Pract Thromb Haemost       Date:  2022-04-11

8.  Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports.

Authors:  Silvia Fernandez; Camille Lenoir; Caroline Samer; Victoria Rollason
Journal:  Pharmacol Res Perspect       Date:  2020-10

9.  Effect of rifampicin on anticoagulation of warfarin: A case report.

Authors:  Ya-Ni Hu; Bo-Ting Zhou; Hua-Rong Yang; Qi-Lin Peng; Xu-Rui Gu; Shu-Sen Sun
Journal:  World J Clin Cases       Date:  2021-02-16       Impact factor: 1.337

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.